| Total n = 157 | Survival n = 137 | Non-survival n = 20 | OR | 95% CI | p-value |
---|---|---|---|---|---|---|
Age | 64.0 (48.0–80.0) | 62.0 (48.0–80.0) | 72.0 (62.8–80.2) | 1.0 | 1.0–1.0 | 0.112 |
 ≥60 years | 92 (58.6%) | 76 (55.5%) | 16 (80.0%) | 3.2 | 1.0–10.1 | 0.046* |
 < 60 years | 65 (41.4%) | 61 (44.5%) | 4 (20.0%) |  |  |  |
Gender | ||||||
 female | 49 (31.2%) | 42 (30.7%) | 7 (35%) | 1.2 | 0.5–3.3 | 0.696 |
 male | 108 (68.8%) | 95 (69.3%) | 13 (65.0%) |  |  |  |
Residence in ICU | 66 (42.0%) | 52 (38.0%) | 14 (70.0%) | 3.8 | 1.4–10.5 | 0.010* |
APACHE II score | 12.0 (6.0–20.0) | 11.0 (1.0–36.0) | 20.0 (6.0–32.0) | 1.1 | 1.0–1.2 | 0.002* |
qSOFA score | ||||||
 2 and 3 | 36 (22.9%) | 26 (19.0%) | 10 (50.0%) | 4.3 | 1.6–11.3 | 0.004* |
 0 and 1 | 121 (77.1%) | 111 (81.0%) | 10 (50.0%) |  |  |  |
Prior hospital stay length | 15.0 (4.0–35.0) | 13.0 (4.0–31.0) | 30.5 (5.8–46.2) | 2.8 | 1.0–1.0 | 0.707 |
 ≥28 days | 53 (33.8%) | 42 (31%) | 11 (55%) | 2.8 | 1.1–7.2 | 0.036* |
 < 28 days | 104 (66.2%) | 95 (69.3%) | 9 (45.0%) |  |  |  |
Comorbidities | ||||||
 Cardiovascular disease | 95 (60.5%) | 82 (59.9%) | 13 (65.0%) | 1.2 | 0.5–3.3 | 0.661 |
 Pneumonia | 73 (46.5%) | 59 (43.1%) | 14 (70.0%) | 3.1 | 1.1–8.5 | 0.030* |
 Cerebrovascular disease | 46 (29.3%) | 42 (30.7%) | 4 (20.0%) | 0.6 | 0.2–1.8 | 0.333 |
 Diabetes mellitus | 36 (22.9%) | 32 (23.4%) | 4 (20.0%) | 0.8 | 0.3–2.6 | 0.739 |
 Chronic liver failure | 29 (18.5%) | 20 (14.6%) | 9 (45.0%) | 4.8 | 1.8–13.0 | 0.002* |
 Chronic renal failure | 27 (17.2%) | 18 (13.1%) | 9 (45.0%) | 5.4 | 2.0–14.9 | 0.001* |
 Solid tumor | 28 (17.8%) | 24 (17.5%) | 4 (20.0%) | 1.2 | 0.4–3.8 | 0.787 |
 Hematologic malignancy | 11 (7.0%) | 9 (6.6%) | 2 (10.0%) | 1.6 | 0.3–7.9 | 0.577 |
 Neutropenia | 12 (7.6%) | 11 (8.0%) | 1 (5.0%) | 0.6 | 0.1–4.9 | 0.637 |
Prior treatments | ||||||
 Indwelling CVC | 88 (56.1%) | 74 (54.0%) | 14 (70.0%) | 2.0 | 0.7–5.5 | 0.184 |
 Indwelling urinary catheter | 67 (42.7%) | 57 (41.6%) | 10 (50.0%) | 1.4 | 0.5–3.6 | 0.480 |
 Invasive MV | 38 (24.2%) | 33 (24.1%) | 5 (25.0%) | 1.1 | 0.4–3.1 | 0.929 |
 Broad-spectrum antibiotics | 31 (19.7%) | 45 (32.8%) | 6 (30.0%) | 0.9 | 0.3–2.4 | 0.800 |
 Surgery | 28 (17.8%) | 26 (19.0%) | 2 (10.0%) | 0.5 | 0.1–2.2 | 0.337 |
 Renal replacement therapy | 9 (5.7%) | 7 (5.1%) | 2 (10.0%) | 2.1 | 0.4–10.7 | 0.389 |
 Chemotherapy | 4 (2.5%) | 3 (2.2%) | 1 (5.0%) | 2.4 | 0.2–23.8 | 0.469 |
Laboratory test results | ||||||
 CRP (mg/dL) | 3.9 (2.3–8.6) | 3.9 (0.1–29.4) | 3.9 (1.2–78.2) | 1.0 | 1.0–1.1 | 0.175 |
 Leukocyte (×109/L) | 8.2 (5.2–11.9) | 8.2 (4.7–12.1) | 8.3 (6.2–11.1) | 1.0 | 0.9–1.1 | 0.706 |
 Neutrophils (×109/L) | 6.5 (3.6–9.5) | 6.6 (3.3–9.9) | 6.3 (4.1–9.1) | 1.0 | 0.9–1.1 | 0.643 |
 ALT (U/L) | 24.6 (13.5–41.9) | 24.4 (3.7–147.0) | 30.2 (1.7–419.1) | 1.0 | 1.0–1.0 | 0.024* |
 SCr (μmol/L) | 63.5 (51.3–83.6) | 62.1 (22.4–1392.0) | 69.0 (37.9–791.0) | 1.0 | 1.0–1.0 | 0.690 |
Appropriate empirical antibiotic therapy | 132 (84.1%) | 117 (85.4%) | 15 (75.0%) | 0.5 | 0.2–1.6 | 0.242 |
 Vancomycin | 40 (25.5%) | 39 (28.5%) | 1 (5.0%) | 0.1 | 0.0–1.0 | 0.052 |
 Carbapenems | 33 (21.0%) | 27 (19.7%) | 6 (30.0%) | 1.7 | 0.6–5.0 | 0.296 |
 Linezolid | 4 (2.5%) | 4 | 0 | – | – | – |